Amgen and Kyowa Kirin Report Positive Long-Term Data for Rocatinlimab in Atopic Dermatitis

Amgen and Kyowa Kirin have shared encouraging top-line results from the Phase III ASCEND trial of rocatinlimab, an investigational T-cell rebalancing therapy for adults and adolescents with moderate to severe atopic dermatitis (AD). ASCEND, part of the eight-trial ROCKET clinical programme, enrolled roughly 2,600 participants to evaluate the long-term safety and efficacy of rocatinlimab at 150mg and 300mg doses administered every four or eight weeks.

The interim analysis focused on adults who completed 24 weeks of treatment in an earlier ROCKET study and received an additional 32 weeks of therapy in ASCEND. Results showed that patients continuing standalone rocatinlimab experienced sustained improvements in itch, skin clearance, disease extent, and severity after one year. The primary endpoint assessed long-term safety, with secondary outcomes confirming durable clinical benefit.

Comprehensive ASCEND data will be presented at an upcoming medical congress or published in a peer-reviewed journal.

16-09-2025